Atreca to Present Analyses of Active B Cell Responses in Nearly 200 Cancer Patients Leading to Identification of More Than 1,000 Antibodies Targeting Non-Autologous Tumor


REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Atreca, Inc. a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, announced today a presentation describing use of the Company’s proprietary Discovery Engine, featuring the Company’s Immune Repertoire Capture® (IRC™) technology, to characterize active B cell immune responses in nearly 200 cancer patients and to identify more than 1,000 tumor-targeting antibodies that bind to “public” tumor antigens. The presentation, entitled “Identification of Functional Antitumor Antibodies from Immunoglobulin Sequence Repertoires of Cancer Patients,” will be delivered by Daniel Emerling, Ph.D., Atreca’s Senior Vice President, Research, on Friday, November 16, 2018 at 1:05 p.m. Western European Time at the 10th Annual Protein and Antibody Engineering Summit (PEGS) Europe, taking place at the Lisbon Congress Center in Lisbon, Portugal, November 12-16, 2018.

“Our unique discovery platform enables us to identify, in an industrialized manner, functional antibodies generated by the active immune responses of cancer patients responding to therapy,” said Tito A. Serafini, Ph.D., Chief Strategy Officer and an Atreca founder. “The results presented at this conference describe analyses of such antibodies from nearly 200 patients, including the identification of more than 1,000 patient antibodies that target non-autologous tumor selectively across multiple tumor types by binding to public antigens. We are using this library of tumor-targeting antibodies to develop therapeutics designed to treat large patient groups, while continuing to discover additional antibodies to add to our library. Our first program to emerge from our platform, ATRC-101, is anticipated to enter clinical development in 2019.”

About Atreca, Inc.

Atreca is a privately held biotechnology company developing novel therapeutics based on a deep understanding of the human immune response. We focus in a unique way on the immune responses of patients in therapeutic areas where such responses are the key phenomenon driving clinical outcomes, enabling us to discover and develop novel immunotherapies. Atreca is advancing a pipeline of candidates designed to engage the human immune response in oncology and other indications, thus driving better therapeutic outcomes. For more information on Atreca, please visit




For Atreca, Inc.
Susan Berland
EVP and Chief Financial Officer
Nancie Steinberg, 212-213-0006, ext. 318
Robert Flamm, 212-213-0006, ext. 364
Alex Gray, 212-213-0006, ext. 355



Source: Atreca, Inc.

Back to news